English  |  正體中文  |  简体中文  |  Items with full text/Total items : 16714/19009 (88%)
Visitors : 5697599      Online Users : 56
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.cnu.edu.tw/handle/310902800/31739


    標題: Serglycin in tumor microenvironment promotes non-small cell lung cancer aggressiveness in a CD44-dependent manner
    作者: Guo, J-Y
    Hsu, H-S
    Tyan, S-W
    Li, F-Y
    Shew, J-Y
    Lee, W-H
    Chen, J-Y
    貢獻者: Acad Sinica, Inst Biomed Sci
    Taipei Vet Gen Hosp, Dept Thorac Surg
    Chia Nan Univ Pharm & Sci, Dept Biotechnol
    Taipei Vet Gen Hosp, Dept Pathol
    Acad Sinica, Genom Res Ctr
    China Med Univ, Inst Clin Med
    Natl Yang Ming Univ, Dept Life Sci
    Natl Yang Ming Univ, Inst Genome Sci
    關鍵字: Epithelial-Mesenchymal Transition
    Nf-Kappa-B
    Hepatocellular-Carcinoma
    Colon-Cancer
    Cd44
    Fibroblasts
    Expression
    Overexpression
    Activation
    Adhesion
    日期: 201-04-277
    上傳時間: 2018-11-30 15:54:53 (UTC+8)
    出版者: Nature Publishing Group
    摘要: Tumor microenvironment (TME) plays an active role in promoting tumor progression. To further understand the communication between TME and tumor cells, this study aimed at investigating the involvement of CD44, a type I cell surface receptor, in the crosstalk between tumor cells and TME. We have previously shown that chondroitin sulfate proteoglycan serglycin (SRGN), a CD44-interacting factor, was preferentially secreted by cancer-associated fibroblasts (CAFs) for promoting tumor growth in breast cancer patients. In this study, we show that SRGN is overexpressed in primary non-small cell lung cancers (NSCLCs), by both carcinoma and stromal cells. Using gain-of-function and loss-of-function approaches, we show that SRGN promotes NSCLC cell migration and invasion as well as colonization in the lung and liver in a CD44-dependent manner. SRGN induces lung cancer cell stemness, as demonstrated by its ability to enhance NSCLC cell sphere formation via Nanog induction, accompanied with increased chemoresistance and anoikis-resistance. SRGN promotes epithelial-mesenchymal transition by enhancing vimentin expression via CD44/NF-kappa B/claudin-1(CLDN1) axis. In support, CLDN1 and SRGN expression are tightly linked together in primary NSCLC. Most importantly, increased expression of SRGN and/or CLDN1 predicts poor prognosis in primary lung adenocarcinomas. In summary, we demonstrate that SRGN secreted by tumor cells and stromal components in the TME promotes malignant phenotypes through interacting with tumor cell receptor CD44, suggesting that a combined therapy targeting both CD44 and its ligands in the TME may be an attractive approach for cancer therapy.
    關聯: Oncogene, v.36, n.17, pp.2457-2471
    Appears in Collections:[生物科技系(所)] 期刊論文

    Files in This Item:

    File Description SizeFormat
    10.1038-onc.2016.404.pdf5427KbAdobe PDF0View/Open
    index.html0KbHTML41View/Open


    All items in CNU IR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback